Private company
Syneos Health, Inc.
American commercial physical and biological research services company2
In its 2023 annual report the company says: “We are a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Our operations are divided into two reportable segments, Clinical Solutions and Commercial Solutions.”75 It is headquartered in Morrisville, United States.2
Last updated Oct 20, 2026.
Overview
- IndustryServices-Commercial Physical & Biological Research2
- HeadquartersMorrisville, United States2
- Incorporated inDE3
- Business address1030 Sync Street, Morrisville, Nc 275603
- Filer categoryLarge accelerated filer3
- Legal formLimited Liability Company2
- LEI549300M1HISD3KQ177972
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O UNITED AGENT GROUP INC., 19810 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 26569302
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
7.5%Operating margin4
4.9%Net margin4
3.5%Revenue growth, 20224
7.6%Return on equity4
0.75×Debt to equity4
$333.5MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Cost of revenue77¢$4.1B
- Selling, general and admin10¢$547.3M
- Other costs6¢$310.1M
- Interest2¢$82.4M
- Income tax1¢$48.1M
- Profit5¢$266.5M
Out of $5.4B in revenue.4
Where each dollar of operating cash went, fiscal 2022
- Capital spending22¢$93.5M
- Share buybacks35¢$150.0M
- Kept or used elsewhere43¢$183.6M
Out of $427.0M of cash from operations.4
Financial statements
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.6B5 | $2.7B6 | $4.4B7 | $4.7B8 | $4.4B4 | $5.2B4 | $5.4B4 |
| Cost of revenue | $1.2B9 | $3.4B7 | $3.6B8 | $3.4B4 | $4.0B4 | $4.1B4 | |
| Gross profit | $403.7M9 | ||||||
| Selling, general and admin | $172.4M5 | $282.6M6 | $406.3M7 | $507.6M8 | $472.7M4 | $570.8M4 | $547.3M4 |
| Operating expenses | $4.8B4 | $5.0B4 | |||||
| Operating income | $155.4M5 | -$28.9M6 | $160.2M7 | $237.8M8 | $293.1M4 | $389.3M4 | $403.2M4 |
| Interest | $12.0M5 | $63.7M6 | $130.7M7 | $129.8M8 | $91.1M4 | $79.3M4 | $82.4M4 |
| Income before tax | $315.2M4 | $314.6M4 | |||||
| Income tax | $21.5M5 | $26.6M6 | $33.0M7 | -$29.5M8 | $10.9M4 | $80.3M4 | $48.1M4 |
| Net income | $112.6M5 | -$138.5M6 | $24.3M7 | $131.3M8 | $192.8M4 | $234.8M4 | $266.5M4 |
| Earnings per share | $2.085 | -$1.856 | $0.237 | $1.278 | $1.854 | $2.264 | $2.594 |
| Earnings per share (diluted) | $2.035 | -$1.856 | $0.237 | $1.258 | $1.834 | $2.244 | $2.584 |
| Shares (weighted, basic) | 103.9M shares4 | 103.0M shares4 | |||||
| Shares (weighted, diluted) | 105.1M shares4 | 103.5M shares4 |
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Cash | $102.5M12 | $321.3M5 | $153.9M5 | $163.7M4 | $272.2M4 | $106.5M4 | $112.0M4 |
| Current assets | $522.6M12 | $1.4B5 | $1.5B6 | $1.6B7 | $1.7B8 | $1.8B4 | $1.9B4 |
| Property, plant and equipment | $222.7M4 | $264.3M4 | |||||
| Goodwill | $5.0B4 | $4.9B4 | |||||
| Intangible assets | $854.1M4 | $680.9M4 | |||||
| Total assets | $1.3B12 | $7.3B5 | $7.3B6 | $7.5B7 | $8.1B8 | $8.2B4 | $8.2B4 |
| Accounts payable | $107.5M4 | $118.6M4 | |||||
| Current liabilities | $466.7M12 | $1.2B5 | $1.5B6 | $1.5B7 | $1.6B8 | $1.7B4 | $1.7B4 |
| Long-term debt | $485.8M12 | $2.9B5 | $2.7B6 | $2.6B7 | $2.9B8 | $2.8B4 | $2.6B4 |
| Total liabilities | $987.0M12 | $4.3B5 | $4.4B6 | $4.4B7 | $4.8B8 | $4.8B4 | $4.7B4 |
| Retained earnings | -$13.0M4 | $167.7M4 | |||||
| Shareholders’ equity | $301.5M6 | $3.0B7 | $2.9B8 | $3.0B4 | $3.2B4 | $3.4B4 | $3.5B4 |
| Shares outstanding | 53.8M shares6 | 104.4M shares6 | 103.4M shares6 | 103.9M shares7 | 103.9M shares8 | 103.8M shares4 | 102.9M shares4 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Cash from operations | $109.5M5 | $198.3M6 | $303.4M7 | $318.5M8 | $425.5M4 | $450.3M4 | $427.0M4 |
| Depreciation and amortization | $235.6M4 | $247.2M4 | |||||
| Stock-based compensation | $65.2M4 | $57.3M4 | |||||
| Capital spending | $31.4M5 | $43.9M6 | $54.6M7 | $64.0M8 | $50.0M4 | $56.8M4 | $93.5M4 |
| Free cash flow | $78.1M | $154.4M | $248.9M | $254.5M | $375.5M | $393.4M | $333.5M |
| Cash from investing | -$340.3M4 | -$105.6M4 | |||||
| Dividends paid | $09 | ||||||
| Share buybacks | $64.5M5 | $06 | $75.0M7 | $56.7M8 | $70.2M4 | $117.5M4 | $150.0M4 |
| Cash from financing | -$277.6M4 | -$339.2M4 |
Corporate structure
Syneos Health, Inc. is part of a group headed by Research Holdings, Inc.. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Syneos Health, Inc.
- Wellington Management Company Filed SC 13G/A on Syneos Health, Inc., latest Jun 9, 2023 (3 filings since Feb 4, 2022)
- VANGUARD GROUP INC Filed SC 13G/A on Syneos Health, Inc., latest Jan 10, 2023 (2 filings since Feb 10, 2022)
- Research Holdings, Inc. Raleigh, North Carolina, United States
- Syneos Health, Inc. Morrisville, North Carolina, United States
- SYNEOS HEALTH UK LIMITED Subsidiary · Farnborough, United Kingdom
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Syneos Health, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $596.3M4 Dec 31, 2022 | $525.0M4 Dec 31, 2021 | +13.6% |
| Accumulated depreciation | $332.0M4 Dec 31, 2022 | $302.3M4 Dec 31, 2021 | +9.8% |
| Property and equipment, net | $264.3M4 Dec 31, 2022 | $222.7M4 Dec 31, 2021 | +18.7% |
| Operating-lease assets (leased space) | $172.8M4 Dec 31, 2022 | $209.4M4 Dec 31, 2021 | −17.5% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $4.9B4 Dec 31, 2022 | $5.0B4 Dec 31, 2021 | −1.2% |
| Intangible assets, net (excluding goodwill) | $680.9M4 Dec 31, 2022 | $854.1M4 Dec 31, 2021 | −20.3% |
| Finite-lived intangibles, gross | $1.8B4 Dec 31, 2022 | $1.9B4 Dec 31, 2021 | −1.3% |
| Accumulated amortization | $1.1B4 Dec 31, 2022 | $998.3M4 Dec 31, 2021 | +15.0% |
| Finite-lived intangibles, net | $680.9M4 Dec 31, 2022 | $854.1M4 Dec 31, 2021 | −20.3% |
Leadership
Who has led Syneos Health, Inc., and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerMichelle Keefe May 18, 2022 to Sep 28, 202313
- Chief executive officerAlistair Macdonald Jan 6, 2017 to Mar 4, 202214
- Chief executive officerD. Jamie Macdonald Nov 6, 2014 to Sep 28, 201615
- PresidentMichael Gibertini Jan 23, 2015 to Sep 16, 201616
- Chief financial officerMichael J. Bonello Jul 7, 2023 to Sep 28, 202317
- Chief financial officerJason M. Meggs Mar 2, 2018 to Feb 24, 202318
- Chief financial officerGregory S. Rush Nov 6, 2014 to Sep 19, 201719
- Chief operating officerMichael Lee Brooks May 18, 2022 to Sep 28, 202320
- Chief operating officerMichael Gibertini Jan 20, 2017 to Jul 3, 201721
- Chief operating officerAlistair Macdonald Nov 6, 2014 to Aug 18, 201622
Board members and other officers (34)
- OfficerStanford Rudnick Apr 10, 2023 to May 17, 202323
- Chief Business OfficerChristian Tucat Sep 6, 2022 to Sep 28, 202324
- SVP, Chief Accounting OfficerDonna Hildebrand Kralowetz Feb 4, 2021 to Sep 28, 202325
- OfficerMichael Lee Brooks Nov 5, 2021 to Mar 4, 202226
- Pres., Commercial SolutionsMichelle Keefe Feb 8, 2019 to Mar 4, 202227
- Pres., Clinical SolutionsPaul Colvin Feb 8, 2019 to Mar 4, 202128
- CAO, GC & SecChristopher L. Gaenzle Nov 6, 2014 to Jan 30, 201829
- Board memberAlfonso G. Zulueta Jan 20, 2022 to Sep 28, 202330
- Board memberBarbara W. Bodem Jan 20, 2022 to Sep 28, 202331
- Board memberMichelle Keefe Jul 20, 2022 to Sep 28, 202332
- Board memberDavid S. Wilkes Jun 16, 2021 to Sep 28, 202333
- Board memberBernadette Connaughton Nov 14, 2019 to Sep 28, 202334
- Board memberJoshua M. Nelson Sep 17, 2018 to May 14, 202135
- Board memberTodd M. Abbrecht Sep 17, 2018 to May 27, 202236
- Board memberJohn M. Dineen Dec 11, 2018 to Sep 28, 202337
- Board memberAlistair Macdonald Jan 6, 2017 to Mar 4, 202214
- Board memberEric Paques Feb 10, 2017 to May 24, 201738
- Board memberLinda S. Harty Mar 3, 2017 to May 27, 202239
- Board memberWilliam E. Klitgaard Mar 3, 2017 to Sep 28, 202340
- Board memberJohn L. Maldonado Aug 11, 2017 to Jun 9, 202141
- Board memberKenneth F. Meyers Nov 1, 2016 to Sep 28, 202342
- Board memberMatthew E. Monaghan Nov 1, 2016 to Sep 28, 202343
- Board memberDavid Y. Norton Feb 4, 2015 to May 24, 201744
- Board memberTeachers Pension Plan Board Ontario May 18, 2015 to Aug 5, 201645
- Board memberCharles C. Harwood Jr. Nov 6, 2014 to Aug 31, 201646
- Board memberD. Jamie Macdonald Nov 6, 2014 to Sep 28, 201615
- Board memberDavid F. Burgstahler Nov 6, 2014 to May 24, 201747
- Board memberJames A. Bannon Nov 6, 2014 to Nov 6, 201448
- Board memberJames T. Ogle Nov 6, 2014 to May 25, 201649
- Board memberRobert W. Breckon Nov 6, 2014 to May 24, 201750
- Board memberSteve Faraone Nov 6, 2014 to Nov 6, 201451
- Board memberTerry Woodward Nov 6, 2014 to Nov 6, 201452
- Board memberRichard N. Kender Dec 9, 2014 to May 24, 201753
- General counselJonathan Olefson Nov 14, 2018 to Sep 28, 202354
Subsidiaries and ownership
Parent company (GLEIF)
Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.
Former names
- INC Research Holdings, Inc.Jul 17, 2014 to Jan 3, 20183
Timeline
- Oct 3, 20238-K Executive or director change55
- Sep 28, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale56
- Sep 6, 20238-K Regulation FD disclosure57
- Aug 3, 20238-K Shareholder vote58
- May 10, 20238-K Other events59
- May 10, 20238-K Results of operations60
- May 10, 20238-K Entered a material agreement61
- May 4, 2023Parent Directly consolidated by Research Holdings, Inc.2
- May 2, 20238-K Executive or director change62
- Mar 30, 20238-K Executive or director change63
- Feb 16, 20238-K Results of operations; Executive or director change64
- Jan 11, 20238-K Regulation FD disclosure65
- Jan 9, 20238-K Results of operations; Executive or director change66
- May 18, 2022New chief executive Michelle Keefe becomes CEO13
- Jan 6, 2017New chief executive Alistair Macdonald becomes CEO14
- Nov 6, 2014New chief executive D. Jamie Macdonald becomes CEO15
- Aug 25, 1996Founded Syneos Health, Inc. is founded2
Calendar
When it reported results
- May 10, 2023Reported quarterly or annual results60
- Feb 16, 2023Reported quarterly or annual results64
- Jan 9, 2023Reported quarterly or annual results66
- Nov 4, 2022Reported quarterly or annual results67
- Aug 2, 2022Reported quarterly or annual results68
- Apr 29, 2022Reported quarterly or annual results69
- Feb 17, 2022Reported quarterly or annual results70
- Nov 3, 2021Reported quarterly or annual results71
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
172 filings to the SEC since October 2021: 3 annual reports, 6 quarterly reports, 26 major events, 109 insider forms, 5 large holders, 23 other. The latest 20:
- Oct 10, 202315-12G EDGAR
- Oct 3, 20238-K EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 20234 FORM 4 SUBMISSION EDGAR
- Sep 28, 2023S-8 POS EDGAR
- Sep 28, 2023S-8 POS EDGAR
- Sep 28, 2023S-8 POS EDGAR
- Sep 28, 2023S-8 POS EDGAR
The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
13 open-market trades by officers, directors and large owners since October 2021: 0 buys and 13 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 28, 2022 | Brooks Michael LeeChief Operating Officer | Sale | 1,502 | $78.00 | $117.2K | Form 4 |
| Jul 21, 2022 | Brooks Michael LeeChief Operating Officer | Sale | 1,502 | $76.00 | $114.2K | Form 4 |
| Jul 20, 2022 | Olefson JonathanGeneral Counsel & Corp Secty | Sale | 2,215 | $75.00 | $166.1K | Form 4 |
| Jul 19, 2022 | Brooks Michael LeeChief Operating Officer | Sale | 1,502 | $74.00 | $111.1K | Form 4 |
| Jul 18, 2022 | KEEFE MICHELLEChief Executive Officer | Sale | 8,333 | $72.81 | $606.7K | Form 4 |
| Jul 18, 2022 | Meggs Jason M.Chief Financial Officer | Sale | 7,500 | $72.81 | $546.1K | Form 4 |
| Jul 8, 2022 | Kralowetz Donna HildebrandEVP, Chief Accounting Officer | Sale | 1,149 | $73.16 | $84.1K | Form 4 |
| May 31, 2022 | Monaghan Matthew E.Director | Sale | 200 | $74.35 | $14.9K | Form 4 |
| Jan 31, 2022 | Kralowetz Donna HildebrandEVP, Chief Accounting Officer | Sale | 1,055 | $90.00 | $95.0K | Form 4 |
| Dec 30, 2021 | Brooks Michael LeeChief Operating Officer | Sale | 93 | $103.00 | $9.6K | Form 4 |
| Dec 23, 2021 | Olefson JonathanGeneral Counsel & Corp Secty | Sale | 1,889 | $100.95 | $190.7K | Form 4 |
| Dec 22, 2021 | Brooks Michael LeeChief Operating Officer | Sale | 93 | $99.00 | $9.2K | Form 4 |
| Dec 20, 2021 | Harty Linda SDirector | Sale | 4,122 | $97.02 | $399.9K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Wellington Management CompanySC 13G/A, 3 filings Feb 4, 2022 to Jun 9, 202372
- VANGUARD GROUP INCSC 13G/A, 2 filings Feb 10, 2022 to Jan 10, 202373
SEC filer profile
How Syneos Health, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSyneos Health, Inc.1
- CIK0001610950
- Employer ID (EIN)27-34031111
- Filer statusLarge accelerated filer1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)8731 Services-Commercial Physical & Biological Research1
- Business address1030 Sync Street, Morrisville, NC 275601
- Phone919-876-93001
- Shares outstanding103,719,179 as of Jul 31, 202311
- Public float$7.3B as of Jun 30, 202274
- On EDGAR sinceJul 17, 20141
- Filings874 in all: 4 (461), 8-K (124), 3 (51), DEFA14A (37), 10-Q (26), SC 13G/A (23), CORRESP (18), 424B7 (15)1
All 41 form types
UPLOAD (15), SC 13D/A (12), 4/A (11), 10-K (9), DEF 14A (8), FWP (5), S-1/A (5), SC 13G (5), DRSLTR (4), S-8 (4), S-8 POS (4), 10-K/A (3), 424B4 (3), DRS/A (3), EFFECT (3), S-1 (3), 8-K/A (2), DEFM14A (2), PREM14A (2), S-3ASR (2), SC 13D (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 5 (1), 8-A12B (1), ARS (1), CERTNAS (1), DRS (1), NT 10-K (1), PRE 14A (1), PRER14A (1)
- Latest filingsAnnual report (10-K) Feb 16, 2023
Quarterly report (10-Q) Aug 9, 2023
Proxy statement (DEF 14A) Apr 12, 2022
Latest 8-K (8-K) Oct 3, 2023
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARMichael Gibertini, President
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARStanford Rudnick, Officer
- 24
- 25
- 26SEC EDGARMichael Lee Brooks, Officer
- 27
- 28
- 29
- 30SEC EDGARAlfonso G. Zulueta, Board member
- 31SEC EDGARBarbara W. Bodem, Board member
- 32SEC EDGARMichelle Keefe, Board member
- 33SEC EDGARDavid S. Wilkes, Board member
- 34SEC EDGARBernadette Connaughton, Board member
- 35SEC EDGARJoshua M. Nelson, Board member
- 36SEC EDGARTodd M. Abbrecht, Board member
- 37SEC EDGARJohn M. Dineen, Board member
- 38SEC EDGAREric Paques, Board member
- 39SEC EDGARLinda S. Harty, Board member
- 40SEC EDGARWilliam E. Klitgaard, Board member
- 41SEC EDGARJohn L. Maldonado, Board member
- 42SEC EDGARKenneth F. Meyers, Board member
- 43SEC EDGARMatthew E. Monaghan, Board member
- 44SEC EDGARDavid Y. Norton, Board member
- 45
- 46SEC EDGARCharles C. Harwood Jr., Board member
- 47SEC EDGARDavid F. Burgstahler, Board member
- 48SEC EDGARJames A. Bannon, Board member
- 49SEC EDGARJames T. Ogle, Board member
- 50SEC EDGARRobert W. Breckon, Board member
- 51SEC EDGARSteve Faraone, Board member
- 52SEC EDGARTerry Woodward, Board member
- 53SEC EDGARRichard N. Kender, Board member
- 54SEC EDGARJonathan Olefson, General counsel
- 55SEC EDGARExecutive or director change
- 56
- 57SEC EDGARRegulation FD disclosure
- 58SEC EDGARShareholder vote
- 59SEC EDGAROther events
- 60SEC EDGARResults of operations
- 61SEC EDGAREntered a material agreement
- 62SEC EDGARExecutive or director change
- 63SEC EDGARExecutive or director change
- 64
- 65SEC EDGARRegulation FD disclosure
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75